Summary

Asia-Pacific postpartum hemorrhage treatment devices market is expected to reach USD 338.02 million by 2032 from USD 213.00 million in 2024, growing at a CAGR of 6.0% in the forecast period of 2025 to 2032.
Market Segmentation:
Asia-Pacific Postpartum Hemorrhage Treatment Devices Market, By Type (Uterine Balloon Tamponade, Uniject Prefilled Injection System, Non-Pneumatic Anti-Shock Garment, Vacuum-Induced Hemorrhage Control Devices, and Others), Condition (Major Postpartum Hemorrhage (More Than 1000 ML), Minor Postpartum Hemorrhage (500-1000 ML), and Massive Postpartum Hemorrhage (2000 ML or More), and Secondary Postpartum Hemorrhage), Patient Type (Primary PPH and Secondary PPH), End User (Hospitals, Maternity Centers, Specialty Clinics, Home Care Settings, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (China, India, Japan, South Korea, Australia, Indonesia, Thailand, Malaysia, Vietnam, Philippines, Taiwan, Singapore, and Rest of Asia-Pacific) - Industry Trends & Forecast To 2032


Overview of Asia-Pacific Postpartum Hemorrhage Treatment Market Dynamics:

Driver

• Rising incidence of postpartum hemorrhage

Restraint

• Side effects associated with the postpartum hemorrhage treatment
Opportunity

• Training and educational programs for proper use of PPH treatment devices

• Market Players:

The key market players operating in the Asia-Pacific postpartum hemorrhage treatment market are listed below:

• Coagulant Therapeutics
• Sterimed Group
• RevMedx
• Maternova Inc.
• Sinapi Biomedical
• BD
• Organon group of companies
• Laborie
• CooperCompanies
• Belmont Medical Technologies
• Krishco Medical Products Pvt. Ltd.
• 3rd Stone Design
• Advin Health Care

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 INTRODUCTION 60
1.1 OBJECTIVES OF THE STUDY 60
1.2 MARKET DEFINITION 60
1.3 OVERVIEW OF THE ASIA-PACIFIC POSTPARTUM HEMORRHAGE TREATMENT DEVICES MARKET 61
1.4 LIMITATIONS 62
1.5 MARKETS COVERED 62
2 MARKET SEGMENTATION 65
2.1 MARKETS COVERED 65
2.2 GEOGRAPHICAL SCOPE 66
2.3 YEARS CONSIDERED FOR THE STUDY 67
2.4 CURRENCY AND PRICING 67
2.5 DBMR TRIPOD DATA VALIDATION MODEL 68
2.6 MULTIVARIATE MODELLING 71
2.7 TYPE LIFELINE CURVE 72
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 73
2.9 DBMR MARKET POSITION GRID 74
2.10 VENDOR SHARE ANALYSIS 75
2.11 MARKET END USER COVERAGE GRID 76
2.12 SECONDARY SOURCES 77
2.13 ASSUMPTIONS 77
3 EXECUTIVE SUMMARY 78
4 PREMIUM INSIGHTS 82
4.1 PESTAL ANALYSIS 84
4.2 PORTERS FIVE FORCES ANALYSIS 85
4.3 INDUSTRY INSIGHTS 86
4.3.1 MICRO AND MACROECONOMIC FACTORS 86
4.3.2 PENETRATION AND GROWTH PROSPECT MAPPING 86
4.3.3 KEY PRICING STRATEGIES 86
4.4 COST ANALYSIS BREAKDOWN 87
4.5 TECHNOLOGY ROADMAP 87
4.6 VALUE CHAIN ANALYSIS 88
4.7 OPPORTUNITY MAP ANALYSIS 88
4.8 HEALTHCARE ECONOMY 88
4.9 REIMBURSEMENT FRAMEWORK 89
4.10 TARIFFS AND ITS IMPACT ON THE MARKET 90
4.10.1 DEFINITION AND IMPORTANCE OF TARIFFS IN THE HEALTHCARE SECTOR 90
4.10.2 ASIA-PACIFIC VS. REGIONAL TARIFF STRUCTURES 90
4.10.3 IMPACT OF TARIFFS ON HEALTHCARE COSTS AND ACCESSIBILITY 90
4.10.4 TARIFF REGULATIONS IN KEY MARKETS 91
4.10.4.1 MEDICARE/MEDICAID TARIFF POLICIES 91
4.10.4.2 CMS PRICING MODELS 91
4.10.4.3 OTHERS 91
4.10.5 TARIFFS ON MEDICAL DEVICES & EQUIPMENT 91
4.10.5.1 IMPORT/EXPORT DUTIES ON MEDICAL EQUIPMENT 91
4.10.5.2 IMPACT ON PRICING AND AVAILABILITY OF HIGH-END MEDICAL TECHNOLOGY 91
4.10.5.3 CASE STUDIES OF TARIFF CHANGES AFFECTING THE INDUSTRY 92
4.10.6 COST BURDEN ON HOSPITALS AND HEALTHCARE FACILITIES 92
4.10.7 TARIFF EXEMPTIONS AND INCENTIVES 92
4.10.8 DUTY-FREE IMPORTS FOR ESSENTIAL MEDICINES AND VACCINES 92
4.10.9 IMPACT OF TRADE WARS ON THE HEALTHCARE SUPPLY CHAIN 93
4.10.10 ROLE OF FREE TRADE AGREEMENTS (FTAS) IN REDUCING TARIFFS 93
5 REGULATORY FRAMEWORK 94
6 MARKET OVERVIEW 97
6.1 DRIVERS 99
6.1.1 RISING INCIDENCE OF POSTPARTUM HAEMORRHAGE 99
6.1.2 ONGOING TECHNOLOGICAL ADVANCEMENTS FOR POSTPARTUM HEMORRHAGE TREATMENTS 100
6.1.3 RISING BIRTH RATES ASSOCIATED WITH AN INCREASE IN THE NUMBER OF POSTPARTUM HEMORRHAGE 101
6.1.4 REGULATORY SUPPORT AND APPROVALS ASSOCIATED WITH THE TREATMENT DEVICES 102
6.2 RESTRAINTS 103
6.2.1 SIDE EFFECTS ASSOCIATED WITH THE POSTPARTUM HEMORRHAGE TREATMENT 103
6.2.2 LIMITED RESEARCH AND DEVELOPMENT FOR PPH TREATMENT 104
6.3 OPPORTUNITIES 105
6.3.1 TRAINING AND EDUCATIONAL PROGRAMS FOR PROPER USE OF PPH TREATMENT DEVICES 105
6.3.2 SUPPORT FROM GOVERNMENTAL AND NON-GOVERNMENTAL ORGANIZATIONS IN PPH DEVICE ADOPTION 106
6.3.3 TELEMEDICINE INTEGRATION TO ENHANCE POSTPARTUM HEMORRHAGE DEVICE USE 107
6.4 CHALLENGES 108
6.4.1 ENVIRONMENTAL IMPACT AND DISPOSAL ISSUES OF SINGLE-USE PPH DEVICES 108
6.4.2 STERILITY CHALLENGES AND INFECTION RISKS IN PPH DEVICES 109
7 ASIA-PACIFIC POSTPARTUM HEMORRHAGE TREATMENT DEVICES MARKET, BY TYPE 110
7.1 OVERVIEW 111
7.2 UTERINE BALLOON TAMPONADE 114
7.2.1 BAKRI BALLOON 115
7.2.1.1 BAKRI POSTPARTUM BALLOON 115
7.2.1.2 BAKRI POSTPARTUM BALLOON WITH RAPID INSTILLATION COMPONENTS 115
7.2.2 FOLEY CATHETER 116
7.2.2.1 STANDARD FOLEY CATHETER 116
7.2.2.2 CONDOM-LOADED FOLEY CATHETER 116
7.3 UNIJECT PREFILLED INJECTION SYSTEM 117
7.3.1 OXYTOCIN-BASED INJECTION SYSTEM 117
7.3.2 CARBETOCIN-BASED INJECTION SYSTEM 117
7.4 NON-PNEUMATIC ANTI-SHOCK GARMENT 118
7.4.1 STANDARD NON-PNEUMATIC ANTI-SHOCK GARMENT 119
7.4.1.1 MEDIUM 119
7.4.1.2 LARGE 119
7.4.2 MODIFIED NON-PNEUMATIC ANTI-SHOCK GARMENT 119
7.4.2.1 MEDIUM 119
7.4.2.2 LARGE 119
7.5 VACUUM-INDUCED HEMORRHAGE CONTROL DEVICES 120
7.5.1 JADA SYSTEM 120
7.5.2 OTHERS 120
7.6 OTHERS 121
7.6.1 COMPRESSION DEVICES 122
7.6.1.1 B-LYNCH 122
7.6.1.2 HAYMAN 122
7.6.1.3 OTHER 122
7.6.2 UTERINE ARTERY LIGATION PRODUCTS 122
7.6.3 OTHERS 122
8 ASIA-PACIFIC POSTPARTUM HEMORRHAGE TREATMENT DEVICES MARKET, BY PATIENT TYPE 123
8.1 OVERVIEW 124
8.2 PRIMARY PPH 127
8.3 SECONDARY PPH 128
9 ASIA-PACIFIC POSTPARTUM HEMORRHAGE TREATMENT DEVICES MARKET, BY CONDITION 129
9.1 OVERVIEW 130
9.2 MAJOR POSTPARTUM HEMORRHAGE (MORE THAN 1000 ML) 133
9.3 MINOR POSTPARTUM HEMORRHAGE (500-1000 ML) 134
9.4 MASSIVE POSTPARTUM HEMORRHAGE (2000 ML OR MORE) 135
9.5 SECONDARY POSTPARTUM HEMORRHAGE 135
10 ASIA-PACIFIC POSTPARTUM HEMORRHAGE TREATMENT DEVICES MARKET, BY DISTRIBUTION CHANNEL 136
10.1 OVERVIEW 137
10.2 DIRECT TENDER 140
10.3 RETAIL SALES 141
10.3.1 OFFLINE SALES 141
10.3.2 ONLINE SALES 141
10.4 OTHERS 142
11 ASIA-PACIFIC POSTPARTUM HEMORRHAGE TREATMENT DEVICES MARKET, BY END USER 143
11.1 OVERVIEW 144
11.2 HOSPITALS 147
11.2.1 PUBLIC HOSPITALS 148
11.2.1.1 TIER 2 148
11.2.1.2 TIER 3 148
11.2.1.3 TIER 1 148
11.2.2 PRIVATE HOSPITALS 149
11.2.2.1 TIER 2 149
11.2.2.2 TIER 3 149
11.2.2.3 TIER 1 149
11.3 MATERNITY CENTERS 150
11.4 SPECIALTY CLINICS 151
11.5 HOME CARE SETTINGS 151
11.6 OTHERS 152
12 ASIA-PACIFIC POSTPARTUM HEMORRHAGE TREATMENT DEVICES MARKET, BY REGION 153
12.1 ASIA-PACIFIC 155
12.1.1 CHINA 162
12.1.2 JAPAN 168
12.1.3 INDIA 175
12.1.4 AUSTRALIA 182
12.1.5 SOUTH KOREA 189
12.1.6 INDONESIA 196
12.1.7 THAILAND 202
12.1.8 MALAYSIA 208
12.1.9 SINGAPORE 214
12.1.10 PHILIPPINES 220
12.1.11 VIETNAM 226
12.1.12 TAIWAN 232
12.1.13 NEW ZEALAND 238
12.1.14 REST OF ASIA-PACIFIC 244
13 ASIA-PACIFIC POSTPARTUM HEMORRHAGE TREATMENT DEVICES MARKET: COMPANY LANDSCAPE 245
13.1 COMPANY SHARE ANALYSIS: GLOBAL 245
14 SWOT ANALYSIS 246
15 COMPANY PROFILES 247
15.1 BD 247
15.1.1 COMPANY SNAPSHOT 247
15.1.2 REVENUE ANALYSIS 248
15.1.3 COMPANY SHARE ANALYSIS 248
15.1.4 SOLUTION PORTFOLIO 249
15.1.5 RECENT NEWS 249
15.2 ORGANON GROUP OF COMPANIES 250
15.2.1 COMPANY SNAPSHOT 250
15.2.2 REVENUE ANALYSIS 250
15.2.3 COMPANY SHARE ANALYSIS 251
15.2.4 PRODUCT PORTFOLIO 251
15.2.5 RECENT DEVELOPMENTS/NEWS 252
15.3 LABORIE 253
15.3.1 COMPANY SNAPSHOT 253
15.3.2 COMPANY SHARE ANALYSIS 253
15.3.3 PRODUCT PORTFOLIO 254
15.3.4 RECENT DEVELOPMENT 254
15.4 COOPERCOMPANIES 255
15.4.1 COMPANY SNAPSHOT 255
15.4.2 REVENUE ANALYSIS 255
15.4.3 COMPANY SHARE ANALYSIS 256
15.4.4 PRODUCT PORTFOLIO 256
15.4.5 RECENT DEVELOPMENT 256
15.5 BELMONT MEDICAL TECHNOLOGIES 257
15.5.1 COMPANY SNAPSHOT 257
15.5.2 COMPANY SHARE ANALYSIS 257
15.5.3 PRODUCT PORTFOLIO 258
15.5.4 RECENT DEVELOPMENT 258
15.6 ADVIN HEALTH CARE 259
15.6.1 COMPANY SNAPSHOT 259
15.6.2 PRODUCT PORTFOLIO 259
15.6.3 RECENT DEVELOPMENTS 259
15.7 ANGIPLAST PRIVATE LIMITED 260
15.7.1 COMPANY SNAPSHOT 260
15.7.2 PRODUCT PORTFOLIO 260
15.7.3 RECENT DEVELOPMENT 260
15.8 COAGULANT THERAPEUTICS 261
15.8.1 COMPANY SNAPSHOT 261
15.8.2 PIPELINE PORTFOLIO 261
15.8.3 RECENT DEVELOPMENT 261
15.9 KRISHCO MEDICAL PRODUCTS PVT. LTD 262
15.9.1 COMPANY SNAPSHOT 262
15.9.2 PRODUCT PORTFOLIO 262
15.9.3 RECENT DEVELOPMENT 263
15.10 MATERNOVA INC. 264
15.10.1 COMPANY SNAPSHOT 264
15.10.2 PRODUCT PORTFOLIO 264
15.10.3 RECENT DEVELOPMENT 264
15.11 REVMEDX 265
15.11.1 COMPANY SNAPSHOT 265
15.11.2 PRODUCT PORTFOLIO 265
15.11.3 RECENT DEVELOPMENT 265
15.12 3RD STONE DESIGN 266
15.12.1 COMPANY SNAPSHOT 266
15.12.2 PRODUCT PORTFOLIO 266
15.12.3 RECENT DEVELOPMENTS 266
15.13 STERIMED GROUP 267
15.13.1 COMPANY SNAPSHOT 267
15.13.2 PRODUCT PORTFOLIO 267
15.13.3 RECENT DEVELOPMENTS 267
15.14 UTAH MEDICAL PRODUCTS, INC. 268
15.14.1 COMPANY SNAPSHOT 268
15.14.2 REVENUE ANALYSIS 268
15.14.3 PRODUCT PORTFOLIO 269
15.14.4 RECENT DEVELOPMENTS 269
15.15 SINAPI BIOMEDICAL 270
15.15.1 COMPANY SNAPSHOT 270
15.15.2 PRODUCT PORTFOLIO 270
15.15.3 RECENT DEVELOPMENTS 270
16 QUESTIONNAIRE 271